Eli Lilly (LLY)

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

This could put pressure on Eli Lilly, which sells a competing drug called Kisunla.

A significant sector rotation is currently underway in equity markets, shifting investor capital away from the mega-cap technology stocks that dominated recent years towards more traditional value and cyclical segments. This trend, gaining significant momentum in 2025, sees sectors such as financial services, basic materials, healthcare, energy, and industrials outperforming,

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.

Here's why investors aren't sure what to make of Nvidia earnings.

Investment bank analysts up and down Wall Street are pounding the table on these stocks.

The U.S. economy currently navigates an intriguing, yet precarious, path as hypothetical Q2 2025 data suggests a robust rebound in Gross Domestic Product (GDP) growth. This economic buoyancy, however, is shadowed by the persistent specter of inflation, with the Personal Consumption Expenditures (PCE) price index stubbornly holding above the

Shares of Eli Lilly (LLY) are testing a resistance level. If they can break through this resistance, a large more higher may follow.

Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.

The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has escalated significantly through 2025, with both nations frequently adjusting and reinstating tariffs, creating a tangled web of

Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop and commercialize treatments.

These two longtime market leaders should continue to perform well.

Investors looking for top growth stocks on the Nasdaq and NYSE may want to consider alternatives to the Invesco QQQ.

Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment.

Patients in UK struggle to obtain Mounjaro drug due to high demand, sharp price increase. Shortages causing stress and health risks.

It doesn't take much to get your money to start working for you on Wall Street.

The financial markets have been a dynamic arena recently, showcasing significant and often dramatic movements in individual stock valuations. These shifts are not random but are deeply rooted in specific corporate catalysts, broader industry trends, and evolving economic landscapes. From the groundbreaking success of new pharmaceutical treatments to pivotal airline

The year 2025 has etched itself into financial history as a testament to the stock market's extraordinary resilience. After a tumultuous April and May, dubbed the "Trump Slump," which saw significant market corrections sparked by aggressive new tariff policies, Wall Street staged a stunning comeback. By June, major indices had

The company beat second-quarter expectations, with the exception of one key metric.